Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
| Revenue (TTM) | $17.32B |
| Gross Profit (TTM) | $9.08B |
| EBITDA | $4.27B |
| Operating Margin | 4.03% |
| Return on Equity | 9.69% |
| Return on Assets | 5.13% |
| Revenue/Share (TTM) | $15.00 |
| Book Value | $6.65 |
| Price-to-Book | 5.53 |
| Price-to-Sales (TTM) | 2.48 |
| EV/Revenue | 3.193 |
| EV/EBITDA | 21.32 |
| Quarterly Earnings Growth (YoY) | 72.20% |
| Quarterly Revenue Growth (YoY) | -0.80% |
| Shares Outstanding | $1.17B |
| Float | $1.09B |
| % Insiders | 0.00% |
| % Institutions | 64.49% |
Volatility is currently contracting
Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly influence jurors.
Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?
Teva Pharmaceutical Industries Limited is executing a successful turnaround, driven by its "Pivot to Growth" strategy and strong innovative medicines performance. Management raised 2026 guidance for Austedo, Ajovy, and Uzedy, targeting $3.7B specialty revenue (17% y/y growth) and a robust pipeline through 2030. Generics and biosimilars remain stable, funding R&D for innovation, while margin improvements and debt reduction enhance the risk/reward profile.
Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026.
TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.
Teva Pharmaceutical Industries NYSE: TEVA reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were largely offset by growth in its innovative medicines portfolio.
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Besides Wall Street's top-and-bottom-line estimates for Teva Pharmaceutical Industries (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Teva's pivot toward branded drugs is benefiting the company's underlying performance and its stock price. While shares have pulled back recently, another big catalyst could play out in the years ahead.
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TEVA and any ticker you trade — then tracks every position and per-strategy win rate.
